Alnylam to provide data on RNAi therapeutics for fibrotic illnesses at The Liver Meeting Alnylam Pharmaceuticals, Inc here . , a leading RNAi therapeutics business, announced today it’ll present many poster presentations at the 61st Annual Getting together with of the American Association for the analysis of Liver Diseases being held in Boston, From October 29 – November 2 Mass, 2010. At the conference, new research related to the business’s pre-clinical and clinical pipeline attempts will be presented, including new data showing effective delivery of RNAi therapeutics to hepatic stellate cells.

2012 Financial Guidance Alnylam expects that its cash now, cash equivalents and total marketable securities balance will be greater than $280 million at December 31, 2012, as compared with its previous assistance of year-end cash of greater than $250 million. The organization's boost to its year-end money guidance is due to upfront obligations from new alliances with Monsanto and Genzyme. Alnylam continues to keep a solid financial profile, ending the third quarter with approximately $296 million in money, which excludes the upfront payment of $22.5 million from our recent alliance with Genzyme that was received in the fourth quarter, stated Michael Mason, Vice President, Finance and Treasurer of Alnylam. Due to our successful business advancement activities, we now believe we will end 2012 with higher than $280 million in cash, that will continue to offer us with a solid balance sheet as we progress our RNAi therapeutics through scientific trials and toward the market.